TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study

Core Insights - Theravance Biopharma (TBPH) shares dropped 26% following the announcement of the failure of the late-stage CYPRESS study for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) [1][6] - The company has decided to discontinue the ampreloxetine program after the study did not meet its primary endpoint [1][3] Study Details - The phase III CYPRESS study was a multi-center, randomized withdrawal study aimed at evaluating the efficacy and durability of ampreloxetine after 20 weeks of treatment [2] - Top-line data indicated that the study failed to meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, with secondary endpoints also not statistically significant [3] Strategic Review and Restructuring - Following the setback, TBPH's strategic review committee is accelerating a review of strategic options, including a potential sale of the company to maximize shareholder value [4] - The company plans to cut its workforce by approximately 50% and reduce operating costs by about 60%, shutting down its entire research and development division [7] Financial Outlook - TBPH anticipates realizing annualized cost savings of approximately $70 million by the third quarter of 2026, which, combined with continued sales of Yupelri, is projected to drive $60–$70 million in annualized cash flow starting in the same quarter [8] - Preliminary net sales of Yupelri in the U.S. for Q4 2025 were reported at $70.6 million, a 6% increase year over year, with full-year sales expected to reach $266.6 million, up 12% [9] Collaboration and Milestones - Theravance collaborates with Viatris for the development and commercialization of Yupelri, which is a treatment for chronic obstructive pulmonary disease (COPD) [10] - The company received a $50 million milestone payment from Royalty Pharma for Trelegy and expects global net sales of Trelegy to reach approximately $3.51 billion in 2026, triggering an additional $100 million in milestone payments [11]